VNA
STOK icon

Valley National Advisers’s Stoke Therapeutics STOK Stock Holding History

Valley National Advisers’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$24K Hold
750
– – ﹤0.01% 484
2025
Q4 		$23K Hold
750
– – ﹤0.01% 490
2025
Q3 		$17K Hold
750
– – ﹤0.01% 491
2025
Q2 		$8K Hold
750
– – ﹤0.01% 611
2025
Q1 		$4K Hold
750
– – ﹤0.01% 667
2024
Q4 		$8K Buy
+750
New +$9.21K ﹤0.01% 580

Other funds holding STOK

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Valley National Advisers's STOK Position: Q1 2026 in Review

Valley National Advisers held its Stoke Therapeutics (STOK) position steady in Q1 2026 at 750 shares worth $24K. The position accounts for ﹤0.01% of the portfolio, ranked #484.

Valley National Advisers first reported a position in STOK in Q4 2024 and has held it in 6 quarters since. 196 funds tracked by Wall St. Rank hold STOK as of Q1 2026.

  • Valley National Advisers held 750 shares of Stoke Therapeutics worth $24K as of Q1 2026.
  • Valley National Advisers left its Stoke Therapeutics share count unchanged in Q1 2026.
  • Stoke Therapeutics made up ﹤0.01% of Valley National Advisers's portfolio in Q1 2026, its #484 holding.
  • Valley National Advisers first reported a position in Stoke Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • 196 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q1 2026.

Based on Valley National Advisers's 13F filing for Q1 2026, filed 15 Apr 2026.